"Our estimated primary completion date is September 2017, and an estimated study completion date of October 2017. When 50 percent of the events required for the primary endpoint have occurred, the Independent Data Monitoring Committee will report an interim assessment of efficacy and safety. So, meaningful clinical data could come as early as the middle of next year, which is halfway through the study, as documented on clinicaltrials.gov. I stretch the word could, and we will continue to make every effort possible to keep our stockholders and the market updated."
Provectus 2015 Third Quarter Business Update
Eric still maintains that the trial is on track. So, according to this, it's possible to start looking for data within the timelines that PVCT has given until they back off of this statement. This question will be asked again at the upcoming con call so I'm sure that's when we'll see if Eric wants to back off of this statement.